Sodium-glucose cotransporter 2 inhibitors in type 1 diabetes: a missed opportunity for cardiovascular protection?

被引：3
作者：
Snaith, Jennifer R. [1 ,2 ]
Greenfield, Jerry R. [1 ,2 ]
机构：
[1] Garvan Inst Med Res, Sydney, NSW, Australia
[2] St Vincents Hosp, Sydney, NSW, Australia
来源：
MEDICAL JOURNAL OF AUSTRALIA | 2022年 / 217卷 / 03期
关键词：
Diabetes mellitus; type; 1; Diabetes complications; INSULIN-RESISTANCE; MORTALITY; COMPLICATIONS; OUTCOMES;
D O I：
10.5694/mja2.51637
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：126 / 128
页数：3
相关论文
共 25 条
[1]   SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice [J].
Ali, Amar ;
Bain, Steve ;
Hicks, Debbie ;
Jones, Phillip Newland ;
Patel, Dipesh C. ;
Evans, Marc ;
Fernando, Kevin ;
James, June ;
Milne, Nicola ;
Viljoen, Adie ;
Wilding, John .
DIABETES THERAPY, 2019, 10 (05) :1595-1622
[2]  
[Anonymous], 2008, Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes
[3]  
Ault A., 2019, MEDSCAPE MED NE 1114
[4]  
Australian Institute of Health and Welfare, 2017, DEATHS PEOPL DIAB AU
[5]   Sodium-glucose co-transporter-2 inhibitors for type 1 diabetes: Not any more? [J].
Czupryniak, Leszek ;
Danne, Thomas ;
Szymanska-Garbacz, Elektra ;
Zozulinska-Ziolkiewicz, Dorota ;
Gumprecht, Janusz ;
Klupa, Tomasz .
DIABETES OBESITY & METABOLISM, 2022, 24 (04) :764-765
[6]   International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors [J].
Danne, Thomas ;
Garg, Satish ;
Peters, Anne L. ;
Buse, John B. ;
Mathieu, Chantal ;
Pettus, Jeremy H. ;
Alexander, Charles M. ;
Battelino, Tadej ;
Javier Ampudia-Blasco, F. ;
Bode, Bruce W. ;
Cariou, Bertrand ;
Close, Kelly L. ;
Dandona, Paresh ;
Dutta, Sanjoy ;
Ferrannini, Ele ;
Fourlanos, Spiros ;
Grunberger, George ;
Heller, Simon R. ;
Henry, Robert R. ;
Kurian, Martin J. ;
Kushner, Jake A. ;
Oron, Tal ;
Parkin, Christopher G. ;
Pieber, Thomas R. ;
Rodbard, Helena W. ;
Schatz, Desmond ;
Skyler, Jay S. ;
Tamborlane, William V. ;
Yokote, Koutaro ;
Phillip, Moshe .
DIABETES CARE, 2019, 42 (06) :1147-1154
[7]  
European Medicines Agency, FORX DAP 5MG SHOULD
[8]  
European Medicines Agency, 2019, First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes
[9]   Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol [J].
Garg, Satish K. ;
Peters, Anne L. ;
Buse, John B. ;
Danne, Thomas .
DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (09) :571-575
[10]   GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs [J].
Giugliano, Dario ;
Scappaticcio, Lorenzo ;
Longo, Miriam ;
Caruso, Paola ;
Maiorino, Maria Ida ;
Bellastella, Giuseppe ;
Ceriello, Antonio ;
Chiodini, Paolo ;
Esposito, Katherine .
CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
123